{
  "docId": "019de517-1302-72c9-b1b1-402f68725e8a",
  "docSlug": "8240d0b9060d59c07a4e5f5063c97322",
  "documentTitle": "Adagio Therapeutics | Results Presentation Deck | 11 slides",
  "authorId": "adagio-therapeutics",
  "authorName": "Invivyd",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 6,
  "pageCount": 11,
  "prevPage": 5,
  "nextPage": 7,
  "slideType": "comparison_table",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 10,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de517-1302-72c9-b1b1-402f68725e8a/6",
  "deckHref": "/decks/019de517-1302-72c9-b1b1-402f68725e8a",
  "deckJsonHref": "/decks/019de517-1302-72c9-b1b1-402f68725e8a.json",
  "deckAnchorHref": "/decks/019de517-1302-72c9-b1b1-402f68725e8a#slide-6",
  "components": [
    {
      "bbox": {
        "h": 0.17,
        "w": 0.402,
        "x": 0.049,
        "y": 0.704
      },
      "kind": "callout",
      "text": "XBB.1.5.10 and EG.5 (one of the dominant variants in the U.S.) are XBB variants with the same spike glycoprotein sequence, including the F456L mutation found in ~80% of the current CDC-tracked variants2-3",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "934280e6-c936-477b-b0a4-94ca689207e9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.34,
        "x": 0.52,
        "y": 0.94
      },
      "kind": "legend",
      "text": "✓ Neutralizing activity in standardized in vitro assays",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b7ddccb7-5ca9-4767-8c63-70028295a5b9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.44,
        "x": 0.049,
        "y": 0.923
      },
      "kind": "source-note",
      "text": "References: 1. VYD222 data generated by CRO using a pseudovirus SARS-CoV-2 neutralizing antibody assay; 2. https://covid.cdc.gov/covid-data-tracker/#variant-proportions (accessed Oct 30, 2023); 3. covSPECTRUM.org",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4e68528c-5bfe-431b-b04f-10b632f78438",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.784,
        "x": 0.107,
        "y": 0.201
      },
      "kind": "table",
      "text": "VARIANT\nWT(D614G)\nDelta\nOmicron\nSUBLINEAGE\nWT(D614G)\nB.1.617.2\nBA.1\nBA.4/5\nBA.4.6\nBF.7\nXBB.1\nXBB.1.5\nXBB.1.16\nXBB.1.5.10/EG.5\nVYD2221\n✓\n✓\n✓\n✓\n✓\n✓\n✓\n✓\n✓\n✓",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fb3f93c5-52d2-45a8-bc2d-89da344e6536",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.91,
        "x": 0.042,
        "y": 0.06
      },
      "kind": "title",
      "text": "VYD222 HAS DEMONSTRATED BROAD IN VITRO NEUTRALIZING ACTIVITY AGAINST VARIOUS PRE-OMICRON AND OMICRON VARIANTS",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "facb06d8-7ef8-48ec-bd2e-7c348d21f1df",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 7,
      "from": 6,
      "beatId": "98297a7b-21bb-4330-add0-fea6bdafb33b",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Visualization",
      "beatSlug": "monroes-sequence-visualization",
      "evidence": "The comparison table and roadmap provide a clear visualization of VYD222's potential",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 9,
      "from": 5,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "d0bf14cf-88e0-4c86-bb16-82a24eeb0889",
      "evidence": "The presentation highlights the urgent need for protection and the potential consequences of inaction",
      "position": 0,
      "objective": "What is the cost of not protecting immunocompromised individuals from COVID-19?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}